
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics Inc. has established a robust scientific foundation that positions it favorably within the competitive landscape of biopharmaceuticals, particularly with its lead product candidate, PLN-101095, demonstrating promising results in recent clinical trials. The company's experienced management team is adept at interacting with regulatory agencies, which mitigates associated risks and enhances the potential for successful drug development and commercialization. Additionally, the innovative integrin-targeted delivery platform presents a significant opportunity to unlock value across various disease areas, further strengthening the outlook for Pliant's stock.
Bears say
Pliant Therapeutics Inc is operating in a high-risk environment characterized by the potential for significant clinical setbacks, particularly given the historical difficulties in developing integrin inhibitors for idiopathic pulmonary fibrosis (IPF). The company faces notable regulatory risks that are common to biotech firms at a similar developmental stage, which could complicate trial designs and impact timelines for product candidates. Compounding these challenges, Pliant's decreased cash position and increased share count contribute to a negative outlook for the company's financial stability and market performance.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares